参考文献/References:
[1] Bertrand OF,Jolly SS,Rao SV,et al.Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention[J].Am J Cardiol,2012,110(4):599-606.
[2] Warkentin TE,Greinacher A,Koster A.Bivalirudin[J].Thromb Haemost,2008,99(5):830-839.
[3] Stone GW,Ware JH,Bertrand ME,et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management:one-year results from the ACUITY Trial[J].JAMA, 2007,298(21):2497-2506.
[4] Stone GW,Witzenbichler B,Guagliumi G,et al.Bivalirudin during primary PCI in acute myocardial infarction[J].N Engl J Med,2008,358(21):2218-2230.
[5] Mehran R,Lansky AJ,Witzenbichler B,et al.Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction(HORIZONS-AMI):1-year results of a randomized controlled trial[J].Lancet,2009,374(9696):1149-1159.
[6] Stone GW,Witzenbichler B,Guagliumi G,et al.Heparin plus a glycoprotein Ⅱb/Ⅲa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction(HORIZONS-AMI):final 3-year results from a multicenter,randomized controlled trial[J].Lancet,2011,377(9784):2193-2204.
[7] Steg PG, van't Hof A, Hamm CW,et al.Bivalirudin started during emergency transport for primary PCI[J].N Engl J Med,2013,369(23):2207-2217.
[8] Zeymer U, van't Hof A, Adgey J, et al.Bivalirudin is superior to heparins alone with bailout GP Ⅱb/Ⅲa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial[J].Eur Heart J, 2014,35(36):2460-2467.
[9] Parodi G,Valenti R,Bellandi B,et al.Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients:RAPID(Rapid Activity of Platelet Inhibitor Drugs)primary PCI study[J].J Am Coll Cardiol,2013,61(15):1601-1606.
[10] Dangas GD,Caixeta A,Mehran R,et al.Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction[J].Circulation,2011,123(16):1745-1756.
[11] Alexopoulos D,Xanthopoulou I,Gkizas V,et al.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction[J].Circ Cardiovasc Interv,2012,5(6):794-804.
[12] Steg PG,Bhatt DL,Hamm CW,et al.Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions:a pooled analysis of patient-level data[J].Lancet,2013,382(9909):1981-1992.
[13] Han YL,Guo JC,Zheng Y,et al.Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction:the BRIGHT randomized clinical trial[J].JAMA,2015,313(13):1336-1346.
[14] Kimmelstiel C, Zhang P, Kapur NK, et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention[J]. Circ Cardiovasc Interv,2011,4(2):171-179.
[15] Clemmensen P, Wiberg S, van't Hof A, et al.Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial(European Ambulance Acute Coronary Syndrome Angiography)[J].JACC Cardiovasc Interv,2015,8(1 pt B):214-220.
[16] Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J].Circulation,2011,124(23):2574-2609.
[17] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC), Steg PG, James SK,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J,2012,33(20):2569-2619.
[18] 中华医学会心血管病学分会介入心脏病学组.2012中国经皮冠状动脉介入治疗指南[J].中华心血管病杂志,2012,40(4):271-277.
[19] American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O'Gara PT, Kushner FG, et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,61(4):e78-e140.
[20] Amsterdam EA,Wenger NK,Brindis RG,et al. 2014 AHA/ACC Guideline for the Management of Patient with Non-ST-Elevation Acute Coronary Syndromes:a report of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,64(24):e139-e228.
相似文献/References:
[1]韩雅君,朱慧,王丽媛,等.虚拟组织学对急性冠状动脉综合征患者斑块评价研究进展[J].心血管病学进展,2015,(5):641.[doi:10.3969/j.issn.1004-3934.2015.05.031]
HAN Yajun,ZHU Hui,WANG Liyuan,et al.Evaluating Plaque in Patients with Acute Coronary Syndrome by Intravascular
Ultrasound with Virtual Histology[J].Advances in Cardiovascular Diseases,2015,(6):641.[doi:10.3969/j.issn.1004-3934.2015.05.031]
[2]郭远林.急性冠状动脉综合征风险评估方法学进展[J].心血管病学进展,2015,(6):681.[doi:10.3969/j.issn.1004-3934.2015.06.007]
GUO Yuanlin,YAN Hongbin.Progress in Tools for Risk Assessment of Acute Coronary Syndromes[J].Advances in Cardiovascular Diseases,2015,(6):681.[doi:10.3969/j.issn.1004-3934.2015.06.007]
[3]丁晓彤 张欣 左海奇 孙雨萌 贾赫 刘宏伟 孙鑫 孙延明 王岚峰 王姝.应激性心肌病诊治进展[J].心血管病学进展,2019,(5):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
DING Xiaotong,ZHANG Xin,ZUO Haiqi,et al.Diagnosis and Treatment of Takotsubo Sydrome[J].Advances in Cardiovascular Diseases,2019,(6):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
[4]白斯特 潘建华 蔡梦珊 姜馨.白介素-1家族在急性冠状动脉综合征发生和发展过程中的机制及治疗现状进展[J].心血管病学进展,2022,(1):64.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.017]
BAI Site,PAN Jianhua,CAI Mengshan,et al.Mechanism and Treatment Status of Interleukin-1 Family in Occurrence and Development of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(6):64.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.017]
[5]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(6):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]